|
1
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
2
|
Raymond AK and Jaffe N: Osteosarcoma
multidisciplinary approach to the management from the pathologist's
perspective. Cancer Treat Res. 152:63–84. 2009. View Article : Google Scholar
|
|
3
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
5
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sampo MM, Tarkkanen M, Kivioja AH,
Taskinen MH, Sankila R and Böhling TO: Osteosarcoma in Finland from
1971 through 1990: A nationwide study of epidemiology and outcome.
Acta Orthop. 79:861–866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Link MP, Goorin AM, Miser AW, Green AA,
Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick
JA, et al: The effect of adjuvant chemotherapy on relapse-free
survival in patients with osteosarcoma of the extremity. N Engl J
Med. 314:1600–1606. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jaffe N, Puri A and Gelderblom H:
Osteosarcoma: Evolution of treatment paradigms. Sarcoma.
2013:2035312013. View Article : Google Scholar :
|
|
11
|
Farber S, Diamond LK, Mercer RD, Sylvester
RF Jr and Wolff JA: Temporary remissions in acute leukemia in
children produced by folic acid antagonist, 4-aminopteroyl-glutamic
acid. N Engl J Med. 238:787–793. 1948. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jain A, Sharma G, Kushwah V, Garg NK,
Kesharwani P, Ghoshal G, Singh B, Shivhare US, Jain S and Katare
OP: Methotrexate and beta-carotene loaded-lipid polymer hybrid
nanoparticles: A preclinical study for breast cancer. Nanomedicine
(Lond). 12:1851–1872. 2017. View Article : Google Scholar
|
|
13
|
Fizazi K, Asselain B, Vincent-Salomon A,
Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T and Pouillart
P: Meningeal carcinomatosis in patients with breast carcinoma.
Clinical features, prognostic factors, and results of a high-dose
intrathecal methotrexate regimen. Cancer. 77:1315–1323. 1996.
View Article : Google Scholar
|
|
14
|
Koga S, Fujimoto T, Hasegawa K and Sueishi
K: Disseminated necrotizing leukoencephalopathy following
intrathecal methotrexate in childhood leukemia (author's transl).
Fukuoka Igaku Zasshi. 67:24–31. 1976.In Japanese. PubMed/NCBI
|
|
15
|
Kim JY, Kim ST, Nam DH, Lee JI, Park K and
Kong DS: Leukoencephalopathy and disseminated necrotizing
leukoencephalopathy following intrathecal methotrexate chemotherapy
and radiation therapy for central nerve system lymphoma or
leukemia. J Korean Neurosurg Soc. 50:304–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan W, Zhang X, Li M, Deng F and Zhang J:
Over expression of miR-200c suppresses invasion and restores
methotrexate sensitivity in lung cancer A549 cells. Gene.
593:265–271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takahashi K, Tsukamoto S, Saito K,
Ohkohchi N and Hirayama K: Complete response to multidisciplinary
therapy in a patient with primary gastric choriocarcinoma. World J
Gastroenterol. 19:5187–5194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cornejo CM, Novoa RA, Krisch RE and Kim
EJ: Low-dose radiotherapy for primary cutaneous anaplastic
large-cell lymphoma while on low-dose methotrexate. Cutis.
98:253–256. 2016.PubMed/NCBI
|
|
19
|
Comandone A, Passera R, Boglione A, Tagini
V, Ferrari S and Cattel L: High dose methotrexate in adult patients
with osteosarcoma: Clinical and pharmacokinetic results. Acta
Oncol. 44:406–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hattinger CM, Pasello M, Ferrari S, Picci
P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert
Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ksiazkiewicz M, Markiewicz A and Zaczek
AJ: Epithelialmesenchymal transition: a hallmark in metastasis
formation linking circulating tumor cells and cancer stem cells.
Pathobiology. 79:195–208. 2012. View Article : Google Scholar
|
|
25
|
Samatov TR, Tonevitsky AG and Schumacher
U: Epithelialmesenchymal transition: Focus on metastatic cascade,
alternative splicing, non-coding RNAs and modulating compounds. Mol
Cancer. 12:1072013. View Article : Google Scholar
|
|
26
|
Fang S, Yu L, Mei H, Yang J, Gao T, Cheng
A, Guo W, Xia K and Liu G: Cisplatin promotes mesenchymal-like
characteristics in osteosarcoma through Snail. Oncol Lett.
12:5007–5014. 2016. View Article : Google Scholar
|
|
27
|
Wang Y, Wang H, Zhou R, Zhong W, Lu S, Ma
Z and Chai Y: Baicalin inhibits human osteosarcoma cells invasion,
metastasis, and anoikis resistance by suppressing the transforming
growth factor-β1-induced epithelial-to-mesenchymal transition.
Anticancer Drugs. 28:581–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L and Xue GB: Catalpol suppresses
osteosarcoma cell proliferation through blocking
epithelial-mesenchymal transition (EMT) and inducing apoptosis.
Biochem Biophys Res Commun. 495:27–34. 2018. View Article : Google Scholar
|
|
29
|
Ohbayashi M, Kubota S, Kawase A, Kohyama
N, Kobayashi Y and Yamamoto T: Involvement of
epithelial-mesenchymal transition in methotrexate-induced pulmonary
fibrosis. J Toxicol Sci. 39:319–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Frescas D and Pagano M: Deregulated
proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the
scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arbini AA, Greco M, Yao JL, Bourne P,
Marra E, Hsieh JT, di Sant'agnese PA and Moro L: Skp2
overexpression is associated with loss of BRCA2 protein in human
prostate cancer. Am J Pathol. 178:2367–2376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lim MS, Adamson A, Lin Z, Perez-Ordonez B,
Jordan RC, Tripp S, Perkins SL and Elenitoba-Johnson KS: Expression
of Skp2, a p27 (Kip1) ubiquitin ligase, in malignant lymphoma:
Correlation with p27 (Kip1) and proliferation index. Blood.
100:2950–2956. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei Z, Jiang X, Liu F, Qiao H, Zhou B,
Zhai B, Zhang L, Zhang X, Han L, Jiang H, et al: Downregulation of
Skp2 inhibits the growth and metastasis of gastric cancer cells in
vitro and in vivo. Tumour Biol. 34:181–192. 2013. View Article : Google Scholar
|
|
34
|
Chan CH, Li CF, Yang WL, Gao Y, Lee SW,
Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF
E3 ligase regulates Akt ubiquitination, glycolysis, herceptin
sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang Y, Tai AW, Tong S and Lok AS: HBV
core promoter mutations promote cellular proliferation through
E2F1-mediated upregulation of S-phase kinase-associated protein 2
transcription. J Hepatol. 58:1068–1073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu HM, Liang Y, Chen Q, Wu QN, Guo YM,
Shen GP, Zhang RH, He ZW, Zeng YX, Xie FY, et al: Correlation of
Skp2 overexpression to prognosis of patients with nasopharyngeal
carcinoma from South China. Chin J Cancer. 30:204–212. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan CH, Morrow JK, Zhang S and Lin HK:
Skp2: A dream target in the coming age of cancer therapy. Cell
Cycle. 13:679–680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin HK, Chen Z, Wang G, Nardella C, Lee
SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al: Skp2
targeting suppresses tumorigenesis by Arf-p53-independent cellular
senescence. Nature. 464:374–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Huang Y, Guan Z, Zhang JL, Su HK,
Zhang W, Yue CF, Yan M, Guan S and Liu QQ: E3-ligase Skp2 predicts
poor prognosis and maintains cancer stem cell pool in
nasopharyngeal carcinoma. Oncotarget. 5:5591–5601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mamillapalli R, Gavrilova N, Mihaylova VT,
Tsvetkov LM, Wu H, Zhang H and Sun H: PTEN regulates the
ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1)
through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 11:263–267.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang H, Regan KM, Wang F, Wang D, Smith
DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor
suppression through ubiquitin-mediated degradation. Proc Natl Acad
Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Inuzuka H, Gao D, Finley LW, Yang W, Wan
L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, et al:
Acetylation-dependent regulation of Skp2 function. Cell.
150:179–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding L, Li R, Han X, Zhou Y, Zhang H, Cui
Y, Wang W and Bai J: Inhibition of Skp2 suppresses the
proliferation and invasion of osteosarcoma cells. Oncol Rep.
38:933–940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
46
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of Snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wei Z, Jiang X, Qiao H, Zhai B, Zhang L,
Zhang Q, Wu Y, Jiang H and Sun X: STAT3 interacts with Skp2/p27/p21
pathway to regulate the motility and invasion of gastric cancer
cells. Cell Signal. 25:931–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X,
Chen S, Chen C and Wang Z: Acquisition of epithelial-mesenchymal
transition is associated with Skp2 expression in
paclitaxel-resistant breast cancer cells. Br J Cancer.
110:1958–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dupuis C, Mercier C, Yang C,
Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville
JL, Duffaud F, Bagarry-Liegey D, et al: High-dose methotrexate in
adults with osteosarcoma: A population pharmacokinetics study and
validation of a new limited sampling strategy. Anticancer Drugs.
19:267–273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang W, Zhang Q, Tian X, Zhao H, Lu W,
Zhen J and Niu X: Population pharmacokinetics of high-dose
methotrexate after intravenous administration in Chinese
osteosarcoma patients from a single institution. Chin Med J (Engl).
128:111–118. 2015. View Article : Google Scholar
|
|
52
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liang SQ, Marti TM, Dorn P, Froment L,
Hall SR, Berezowska S, Kocher G, Schmid RA and Peng RW: Blocking
the epithelial-to-mesenchymal transition pathway abrogates
resistance to anti-folate chemotherapy in lung cancer. Cell Death
Dis. 6:e18242015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fidler IJ: The organ microenvironment and
cancer metastasis. Differentiation. 70:498–505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang H, Kobayashi R, Galaktionov K and
Beach D: p19Skp1 and p45Skp2 are essential elements of the cyclin
A-CDK2 S phase kinase. Cell. 82:915–925. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Totary-Jain H, Sanoudou D, Dautriche CN,
Schneller H, Zambrana L and Marks AR: Rapamycin resistance is
linked to defective regulation of Skp2. Cancer Res. 72:1836–1843.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Koo KH, Kim H, Bae YK, Kim K, Park BK, Lee
CH and Kim YN: Salinomycin induces cell death via inactivation of
Stat3 and downregulation of Skp2. Cell Death Dis. 4:e6932013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tang H, Fan D, Lei CT, Ye C, Gao P, Chen
S, Meng XF, Su H and Zhang C: MAD2B promotes tubular
epithelial-to-mesenchymal transition and renal tubulointerstitial
fibrosis via Skp2. J Mol Med (Berl). 94:1297–1307. 2016. View Article : Google Scholar
|
|
59
|
Yang Y, Lu Y, Wang L, Mizokami A, Keller
ET, Zhang J and Fu J: Skp2 is associated with paclitaxel resistance
in prostate cancer cells. Oncol Rep. 36:559–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Huang T, Yang L, Wang G, Ding G, Peng B,
Wen Y and Wang Z: Inhibition of Skp2 sensitizes lung cancer cells
to paclitaxel. OncoTargets Ther. 10:439–446. 2017. View Article : Google Scholar
|
|
61
|
Chan CH, Morrow JK, Li CF, Gao Y, Jin G,
Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, et al: Pharmacological
inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem
cell traits and cancer progression. Cell. 154:556–568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mou H, Guo P, Li X, Zhang C, Jiang J, Wang
L, Wang Q and Yuan Z: Nitidine chloride inhibited the expression of
S phase kinase-associated protein 2 in ovarian cancer cells. Cell
Cycle. 16:1366–1375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X,
Zhou X and Wang Z: Rottlerin exhibits anti-cancer effect through
inactivation of S phase kinase-associated protein 2 in pancreatic
cancer cells. Am J Cancer Res. 6:2178–2191. 2016.PubMed/NCBI
|
|
64
|
Feng S, Wang Y, Zhang R, Yang G, Liang Z,
Wang Z and Zhang G: Curcumin exerts its antitumor activity through
regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.
OncoTargets Ther. 10:2377–2388. 2017. View Article : Google Scholar
|
